• About us
• Contact

Advertisement

Organisation › Details

Forbion Capital Partners (NL)

Forbion is a dedicated life sciences venture capital firm with offices in The Netherlands, Germany and Boston. Forbion invests in life sciences companies that are active in the (bio-) pharmaceutical space. Forbion manages €3 billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development. Forbion’s current team consists of over 30 life sciences investment professionals that have built an impressive performance track record since the late nineties with investments in over 95 companies across 8 funds. Forbion’s record of sourcing, building and guiding life sciences companies has resulted in many breakthrough therapies and valuable exits. Recent portfolio company successes include Inversago, Vectiv Bio, Versanis, Gyroscope, NewAmsterdam Pharma (NASDAQ: NAMS), Engene (NASDAQ: ENGN), and Replimune (NASDAQ: REPL). Besides financial objectives, Forbion selects investments that will positively affect the health and well-being of patients. The firm is a signatory to the United Nations Principles for Responsible Investment. Forbion operates a joint venture with BGV, the manager of seed and early-stage funds, especially focused on Benelux and Germany. *

 

	Start	2006-12-01 splitoff
	Group	Forbion (Group)
	Predecessor	ABN AMRO Capital Life Sciences
	Industry	venture capital
	Industry 2	LIFE SCIENCES
	Person	Slootweg, Sander (Forbion Capital Partners 20111 Managing Partner before ABN AMRO Capital)
	Person 2	Kersten, Dirk (Forbion 202501– promoted to Managing Partner joined 201810 before Inkef Capital + Gilde Healthcare)
	Region	Naarden
	Country	Netherlands
	Street	2-35 Gooimeer
	City	1411 DC Naarden
	Tel	+31-35-699-3000
		Address record changed: 2024-10-19
Basic data	Employees	B: 11 to 50 (2024-01-09)
	Currency	EUR
	Annual sales	3,000,000,000 (capital under management (2024) 2024-01-09)
		* Document for »About Section«: Forbion Capital Partners. (1/9/24). "Press Release: Forbion Portfolio Company Aiolos Bio, Inc. (Aiolos) to Be Acquired by GSK for up to $1.4 Billion".
		Record changed: 2025-01-13

Advertisement

More documents for Forbion (Group)

• [1] Forbion Capital Partners. (1/13/25). "Press Release: Forbion Promotes Dirk Kersten to Managing Partner and Strengthens US Team". Naarden....
• [2] Orbis Medicines ApS. (1/6/25). "Press Release: Orbis Medicines Raises EUR 90 Million Series A Funding Round to Develop Pipeline of Oral Macrocycles". Copenhagen....
• [3] Forbion Capital Partners. (10/15/24). "Press Release: Forbion Raises in Excess of €2 Billion for Two New Funds". Naarden....
• [4] LoQus23 Therapeutics Ltd.. (10/2/24). "Press Release: LoQus23 Therapeutics Announces £35 Million (c.$43 Million) Series A Financing to Advance Its Small Molecule Somatic Expansion Inhibition Therapy for Huntington’s Disease". Cambridge....
• [5] Forbion Capital Partners. (9/11/24). "Press Release: Forbion Leads $14m Series A in Solasta Bio to Advance Development and Commercialisation of First-in-class Sustainable Crop Protection Solutions". Naarden....
• [6] AIRNA Corporation. (7/31/24). "Press Release: AIRNA Raises Oversubscribed $60 Million Financing to Advance New Class of RNA Editing Medicines and Progress Best-in-Class AATD Program into the Clinic". Cambridge, MA & Tübingen....
• [7] Beacon Therapeutics Holdings Ltd.. (7/3/24). "Press Release: Beacon Therapeutics Raises $170 Million in Series B Funding to Advance Development of Ophthalmic Gene Therapies". London & Cambridge, MA....
• [8] Forbion Capital Partners. (6/27/24). "Press Release: Forbion Strengthens US Presence, Hiring Biotech Industry Leader and Opening Boston Office". Naarden....
• [9] Forbion Capital Partners. (6/20/24). "Press Release: Forbion Announces First Close of Its New BioEconomy Fund I – Backing Biotech-enabled Companies Aiming to Impact the Future of Our Planet". Amsterdam....
• [10] Forbion Capital Partners. (6/18/24). "Press Release: Forbion Co-leads $190 Million Financing of Marea Therapeutics". Naarden....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.